The current financial score of Collplant Biotechnologies Ltd is 5.81. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 73.00K, representing a year-over-year decrease of 96.45%, while its net profit experienced a year-over-year decrease of 113.29%.
The current valuation score of Collplant Biotechnologies Ltd is 7.67. Its current P/E ratio is -4.29, which is -93.25% below the recent high of -0.29 and -212.50% above the recent low of -13.41.
No earnings forecast score is currently available for Collplant Biotechnologies Ltd. The Biotechnology & Medical Research industry's average is 8.12. The average price target is 11.00, with a high of 11.00 and a low of 11.00.
The current price momentum score of Collplant Biotechnologies Ltd is 7.16. Currently, the stock price is trading between the resistance level at 8.21 and the support level at 1.25, making it suitable for range-bound swing trading.
The current institutional shareholding score of Collplant Biotechnologies Ltd is 3.00. The latest institutional shareholding proportion is 13.14%, representing a quarter-over-quarter decrease of 27.21%. The largest institutional shareholder is James Simons, holding a total of 61.50K shares, representing 0.00% of shares outstanding, with 25.00% decrease in holdings.
The current risk assessment score of Collplant Biotechnologies Ltd is 1.11. The company's beta value is 0.66. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.